Cefepime hydrochloride
Based on 16 publication(s) in Google Scholar
Cefepime (BMY-28142) hydrochloride is a broad-spectrum, blood-brain barrier-permeable cephalosporin antibiotic with hPON1 inhibitory activity, with an IC50 of 21.115 mM and a Ki of 35.092 mM. Cefepime hydrochloride inhibits hPON1 via a non-competitive mechanism and blocks GABAA receptors. Cefepime hydrochloride penetrates the outer membrane of Gram-negative bacteria, inhibits the growth of Gram-positive and Gram-negative bacteria, and does not induce the production of β-lactamase.
For research use only. We do not sell to patients.
- CAS No.: 107648-80-6
- Formula: C19H26Cl2N6O5S2
- Molecular Weight:553.48
-
Storage:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cefepime hydrochloride
More- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Pharmaceutics. 2023 Nov 30;15(12):2705. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- Int J Antimicrob Agents. 2025 Jun 9:107551. [Abstract]
- Antimicrob Agents Chemother. 2025 May 15:e0010225. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Glob Antimicrob Resist. 2025 Jul 7:44:265-271. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- Vet Microbiol. 2024 May:292:110046. [Abstract]
- J Antibiot (Tokyo). 2023 Apr;76(4):225-235. [Abstract]
- Res Sq. 2026 Mar 9.
- Patent. US20240209004A1.
- bioRxiv. 2024 May 10.
Customer Validation & Images
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
All Antibiotic Isoforms
More
Biological Activity
Cefepime (18 h) hydrochloride potently inhibits most isolates of Gram-negative aerobic bacteria. Among these pathogens, the MIC90 value is ≤1 mg/L for most Enterobacteriaceae, 16 mg/L for Pseudomonas aeruginosa, and ≤0.12 mg/L for Haemophilus influenzae, Neisseria gonorrhoeae and Branhamella catarrhalis[4].
Cefepime (18-48 h) hydrochloride inhibits Gram-positive bacterial isolates, with an MIC90 value of ≤ 4 mg/L against staphylococci and an MIC90 value of ≤ 0.25 mg/L against most streptococci, but shows limited activity against Enterococcus faecalis, Listeria monocytogenes and Bacteroides species[4].
Cefepime hydrochloride exhibits stable in vitro activity across different culture media, pH values, and inoculum sizes. For most isolates, the difference between its MIC and MBC values is extremely small, but the MBC values of Pseudomonas aeruginosa and Staphylococcus aureus in human serum are higher[4].
Cefepime (2-8×MIC; 2-24 h) hydrochloride exhibits concentration-dependent bactericidal activity against Enterobacter cloacae (with the strongest activity and no regrowth observed at 8×MIC), sustained bactericidal activity against Pseudomonas aeruginosa, but only limited transient activity against Methicillin (HY-121544)-resistant Staphylococcus aureus[4].
Cefepime (1 mM) hydrochloride exhibits high stability against almost all tested plasmid-mediated and chromosome-mediated bacterial β-lactamases, and is only slightly hydrolyzed by the PSE-2 enzyme[4].
Cefepime hydrochloride is a weak inhibitor of most bacterial β-lactamases, exhibiting only weak activity against Proteus vulgaris Ic enzyme and Pseudomonas aeruginosa Id enzyme, with an IC50 value of > 400 mg/L against the key clinical β-lactamases TEM-1 and P99[4].
Cefepime hydrochloride exhibited only marginal differences in MIC values among Escherichia colipermeability mutants, whereas an 8-fold difference was observed among Pseudomonas aeruginosapermeability mutants, indicating that its ability to enhance bacterial cell wall penetration is limited[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cefepime (250-500 mg/kg; intravenous bolus) hydrochloride does not increase the susceptibility to pentylenetetrazol (PTZ)-induced convulsions in normal male ICR mice[3].
Cefepime (250-500 mg/kg; intravenous bolus) hydrochloride significantly increases the average seizure grade to 3.3 in the low-current electroshock-induced seizure model of normal male ICR mice, while the 250 mg/kg dose increases the average seizure grade to 2.0[3].
Cefepime (500 mg/kg; intravenous bolus) hydrochloride induces convulsions in 2 out of 3 normal male ICR mice, and elicits electroencephalogram spike waves in the parietal cortex of 1 mouse following low-current electroshock stimulation[3].
Cefepime (500 mg/kg; intravenous bolus) hydrochloride significantly increases the average seizure grade induced by low-current electroconvulsive shock to 4.0 in cornea-kindled male ICR mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 107648-80-6
-
Appearance Solid
-
Molecular Weight 553.48
-
Formula C19H26Cl2N6O5S2
-
Color White to off-white
-
SMILES
OC(C(N(C1=O)[C@@](SC2)([H])[C@@H]1NC(/C(C3=CSC(N)=N3)=N\OC)=O)=C2C[N+]4(CCCC4)C)=O.[Cl-].Cl
-
Synonyms
BMY-28142 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
Pharmaceutics
2023 Nov 30;15(12):2705. PMID: 38140046 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Jun 9:107551. PMID: 40499596 -
Antimicrob Agents Chemother
Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO. [Abstract]2025 May 15:e0010225. PMID: 40372025 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989
Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
Activities of new β-lactam/β-lactamase inhibitors (Cefepime, et al.) against AmpC-hyperproducing E. cloacae complex and Klebsiella aerogenes were evaluated.
-
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Glob Antimicrob Resist
Genomic characterization of carbapenem-resistant Pseudomonas aeruginosa from ICU admission screening in Hanoi, Vietnam, 2023. [Abstract]2025 Jul 7:44:265-271. PMID: 40633763 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594
Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
Antibiotic sensitivity of K. pneumoniae Kp81 and its derivatives.
-
Vet Microbiol
Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]2024 May:292:110046. PMID: 38471428
Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 May:292:110046. [Abstract]
MICs for 16 antimicrobial agents against 381 strains of P. multocida from pigs. a AMP: ampicillin, AMX: amoxicillin, CEF: ceftiofur, CIP: ciprofloxacin, COL: colistin, CPM: Cefepime, DOX: doxycycline, ENR: enrofloxacin, ERY: erythromycin, FFC: florfenicol, GEN: gentamicin, IPM: imipenem, SPT: spectinomycin, TET: tetracycline, TGC: tigecycline, TIL: tilmicosin. b NA: breakpoint not available. c veterinary-specific breakpoints applicable to porcine P. multocida from CLSI VET01S ED7:2024; light grey shading – susceptible, dark grey shading – intermediate, black shading – resistant.
-
J Antibiot (Tokyo)
Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new β-lactam/β-lactamase inhibitor combinations and on virulence of Escherichia coli isolates. [Abstract]2023 Apr;76(4):225-235. PMID: 36726014
Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: J Antibiot (Tokyo). 2023 Apr;76(4):225-235. [Abstract]
Susceptibility patterns of E. coli isolates (n = 140) towards different β-Lactams singly and in combination with β-Lactamase inhibitors (CFP Cefoperazone, CAZ Ceftazidime, FEP Cefepime). The results showed that cephalosporins were effective against E. coli isolates at the following rates: cefoperazone (52.9%), ceftazidime (43.5%), and Cefepime (32.1%).
-
-
-
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Türkeş C, et al. Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem. 2015;30(4):622-628. [Content Brief]
[2]. Pais GM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022;61(7):929-953. [Content Brief]
[3]. Tanaka A, et al. Convulsive liability of cefepime and meropenem in normal and corneal kindled mice. Antimicrob Agents Chemother. 2014;58(8):4380-4383. [Content Brief]
[4]. Neu HC, et al. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17(4):441-452. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cefepime hydrochloride Related Classifications
HY-108877 Related Classifications
Powered by Bioz
- Cefepime
- 107648-80-6
- BMY-28142
- BMY28142
- BMY 28142
- Antibiotic
- Bacterial
- GABA Receptor
- nosocomial infections
- blood-brain barrier
- gram-negative bacteria
- pneumonia
- gram-positive bacteria
- complicated urinary tract infections
- GABA_A receptors
- anaerobic Bacteroides species
- TEM plasmid β-lactamase
- hPON1
- Inhibitor
- inhibitor
- inhibit